DMRA
The table below shows Damora Therapeutics, Inc.'s income statement line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - |
| Cost of revenue | - | - | - | - | - | - |
| Gross profit | - | - | - | - | - | - |
| R&D | $26.88M | $6.40M | $23.77M | $48.21M | $38.49M | $24.63M |
| SG&A | $9.69M |
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| $10.50M |
| $12.69M |
| $13.00M |
| $13.74M |
| $9.01M |
| Operating income | -$210.87M | -$22.26M | -$39.91M | -$61.21M | -$52.23M | -$33.64M |
| Income tax | $50.00K | $41.00K | $0.00 | $0.00 | $0.00 | $0.00 |
| Net income | -$209.84M | -$21.44M | -$38.35M | -$61.62M | -$51.75M | -$34.84M |
| EPS (diluted) | $3.98 | -$18.53 | -$36.08 | -$2.43 | -$2.05 | - |